SENS
Senseonics Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.57
P/S
7.57
EV/EBITDA
-5.24
DCF Value
$-23.06
FCF Yield
-23.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
45.0%
Operating Margin
-184.9%
Net Margin
-189.9%
ROE
-104.2%
ROA
-55.5%
ROIC
-66.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $14.3M | $-20.8M | $-0.50 |
| FY 2025 | $35.3M | $-69.1M | $-1.66 |
| Q3 2025 | $8.1M | $-19.5M | $-0.43 |
| Q2 2025 | $8.3M | $-15.5M | $-0.52 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.05
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.